Company Update

Shree Ganesh Remedies Limited has released its Investor Presentation for the financial results of the quarter ended June 30, 2025. The company experienced moderated Q1 FY26 performance due to repricing of CRAMS contracts, European market headwinds, and intensified domestic competition, which also led to moderated EBITDA margins.

Despite near-term challenges, the company remains confident in its CRAMS vertical, actively engaging in new projects.

Strategic investments include establishing a new pilot facility this quarter and accelerating Block 7 construction.

Progress at the Dahej site continues, building infrastructure for significant future scale-up.